L
iver diseases affect billions worldwide and are associated with significant morbidity and mortality as well as high costs on medical expenditure and work loss. [1] [2] [3] [4] [5] [6] Moreover, the most common liver diseases, namely hepatitis B, hepatitis C, and Nonalcoholic Fatty Liver Degeneration (NAFLD), are frequently asymptomatic until late in the disease course and are thus underdiagnosed. 2, 4, 6 Early identification may allow affected individuals to make valuable lifestyle modifications 1, [7] [8] [9] as well as consider treatment. Effective treatment modalities are now available and were found to be cost-effective when initiated before the onset of cirrhosis and liver failure, 10, 11 favoring early diagnosis in the asymptomatic phase. Moreover, from the public health standpoint, identification of asymptomatic carriers of hepatitis B and C viruses (HBV and HCV) may help limit the spread of these agents, currently the most frequent blood-borne agents in the United States. 1, 12 Available diagnostic methods are costly and are hampered by changing or normal levels (serologic tests and liver enzymes levels) in different disease stages. 4, 5, 7, 13, 14 Additionally, decisions regarding treatment initiation are based on the level of disease progression. Although various other modalities have been developed, liver biopsy remains the gold standard for evaluating liver disease progression. However, this technique is associated with high cost, significant discomfort and potential life threatening complications. 15 Thus a search is warranted for novel diagnostic methods and additional techniques for the evaluation of liver disease progression.
As complementary medicine is gaining momentum with an increase in the proportion of the population seeking nonconventional therapies, 16 new diagnostic techniques are also being developed. One of these techniques, which has gained popularity in various settings throughout the world, is based on a branch of complementary medicine: neuroreflexology. It is based on the measurement of the skin electrical impedance of predetermined areas on the hands and feet (Fig. 1) .
The rationale is that each internal organ has corresponding representative zones on the skin, the physical parameters of which are in correspondence with the condition of the represented organs.
This method, sponsored by various commercial companies, is considered as ''complementary'' medicine, and has seldom been the subject of conventional scientific study. 17 The objectives of the present study are to determine the effectiveness of this diagnostic test, specifically the Medex device (Medex Screen Ltd.), in diagnosing liver disease caused by hepatitis B, C, and NAFLD and to determine the degree of liver disease progression.
METHODS

Study Design
The study was conducted in the liver disease clinic at the Tel-Aviv Sorasky Medical Center, Israel, during 2002, in 2 parts:
Part 1: The first part of the study was fashioned as a blinded case control study aimed at comparing the efficacy of the ''Medex Test'' in detecting liver disease with conventional methods. First demographic data and clinical history were recorded. Additionally, subjects completed a questionnaire including past medical history, intravenous drug and alcohol use, prior blood products treatment and medication use. Patients and healthy volunteers subsequently underwent a Medex Test by one of 2 blinded operators. All subjects were evaluated by a hepatologist who was blinded to the Medex Test results. Diagnosis was verified and additional liver diseases were excluded. Tests preformed within 3 months of the Medex Test were considered current and additional tests were completed as needed.
Part 2: The second part of the study was also fashioned as a blinded case-control study, and compared the degree of necroinflammation measured by the Medex Test with biopsy results. The grading of liver necroinflammation in the biopsies (expressed as histologic grade, on a scale of 0-4 according to Batts and Ludwig 18 ) was compared with the Medex Test grading (also expressed on a scale of 0-4). We also recorded the fibrosis stage by using the Batts & Ludwig scale for fibrosis. 18 Three patients had a fibrosis stage results that were between 2 stages (eg, 2 to 3) and for the purpose of statistical analysis was considered as the mean of the 2 (eg, 2 to 3 was considered as 2.5).
Study Population Part 1
Patients treated at the liver disease unit for HBV and HCV infection and NAFLD were recruited as well as healthy volunteers. Participation in the study was proposed to all patients during follow-up outpatient visits during the recruitment phase (January to April, 2002). Healthy volunteers were recruited from hospital personnel and patient's chaperons. Patients and healthy controls were 18 years or older.
Inclusion Criteria-Patients
Chronic hepatitis C was defined as: positive HCV antibody by a third generation enzyme-linked immunosorbent assay and a positive HCV ribonucleic acid by a commercial Roche polymerase chain reaction assay with a sensitivity at least 50 IU/mL.
Chronic hepatitis B was defined as: (1) Positive HbsAg and HbcAbIgG by a standard commercial kit, (2) Compatible liver biopsy (optional), (3) Elevated alanine aminotransferase, if liver biopsy is not available.
NAFLD was defined as: (1) Imaging findings (abdominal ultra sound and/or computed tomography and/or magnetic resonance imaging) compatible with a diagnosis of NAFLD.
2,19-21 (2) If NAFLD is not definitely diagnosed by imaging, then a compatible liver biopsy is mandatory.
Exclusion Criteria-Patients
Patients were excluded if they had any single criterion of the criteria detailed below. 
Part 2
In the second part of the study treatment naive patients with chronic HCV infection and a current biopsy were included. The same exclusion and inclusion criteria as in part 1 for HCV patients were used in the second part. The study population in the 2 parts did not include the same patients.
Medex Test
In this study we have evaluated a device developed by Medex Screen Ltd. (Arad, Israel). It consists of a handheld, pressure operated, electrode and an additional electrode held by the patient in the opposite hand (Fig. 2) . Through the electrode a small, unfelt, electrical current is applied to the defined skin areas called the dermal-visceral zones. The device measures the skin impedances in these areas (in kO), which are then processed by the device software (patent number US 10/210,223 ''Non-invasive method for internal diseases' diagnosis''). Before testing, the skin is cleaned with 70% ethyl alcohol solution to avoid possible effects of sebum or humidity on the skin. Measurements are conducted using the skin electrode on 24 predetermined zones on the hands and feet. The measurements are repeated twice. Between the 2 measurements standard transcutaneous electrical stimulation of the specific skin areas is performed (1 min, 100 Hz, 25 mA). Subsequently, the measurements are processed by the device software. The normal value range is created by incorporating the patient's measurements into a preset algorithm. Deviations from the normal range are recorded and studied (Fig. 3) .
Safety Considerations
The electrical measurements are performed with an electrical current of up to 20 mA (voltage of 5 V) lasting approximately 0.5 seconds. This low electric current is considered very safe and is not associated with skin or any other damage.
Ethical Considerations
The study was approved by the hospital's Helsinki ethical committee for clinical investigations. All patients provided written informed consent before entering the study.
Statistical Analysis
Statistical analysis was conducted using the SPSS for Windows 10.0 program. The Medex Test diagnosis was statistically compared with the results obtained from the conventional diagnostic methods. The statistical analysis estimated agreement between the Medex Test diagnosis and the results of the conventional diagnostic examinations. A standard measure of agreement (Cohen k) between the 2 variables was estimated. In addition, all measures of agreement (sensitivity, specificity, positive, and negative predictive values) for the Medex Test diagnosis were calculated using the conventional diagnosis as the gold standard. P values <0.01 were considered significant. To evaluate whether there is a covariate effect in the accuracy of the test (sex, age, and time since biopsy) a multivariate logistic regression was performed.
To achieve a significance level of 95%, a sample size of 200 valuable subjects will be sufficient for estimation of k between 90% and 100%.
RESULTS
A total of 113 patients with liver disease and 85 volunteers were evaluated during the study. Cases and controls were age matched (P value for difference NS), with an average age of 47 years in cases and 46 years for control (range 21 to 75 for cases and 22 to 76 for controls). Cases and control did not match by sex, (P = 0.004) with females comprising 68.2% of health volunteers and 47.8% of patients with liver disease. The most common diagnosis was HCV infection with 91 patients, followed by NAFLD with 12 patients and 10 with HBV infection. Basic demographic characteristics are presented in Table 1 .
In the first part of the study, the Medex Test correctly identified 96/113 of cases and 80/85 of controls. The sensitivity of the method was 85 ± 7% (sensitivity ± 95% confidence interval), and the specificity was 94.1 ± 5% (specificity ± 95% confidence interval). Positive and negative predictive values were 95% and 82.5%, respectively. There was a statistically significant agreement between the results of the Medex Test and the clinical diagnosis k = 0.777, P<0.001.
A multivariate logistic regression was performed to evaluate whether the accuracy of the test in predicting liver disease depends on sex or age. No significant interaction was found between sex or age and Medex Test in the prediction of disease, z = 0.157, P = 0.692 and z = 0.248, P = 0.957 (for sex and age, respectively).
The size of the sample did not afford statistical significance for a subgroup analysis evaluating accuracy of prediction for specific disease groups (HCV, HBV, NAFLD). Sensitivity was high regardless of the liver disease with a rate of 100% and 92.5% for HBV and NAFLD, respectively, and a slightly lower rate of 82.5% for HCV infection.
In the second part of the study, 60 treatment naive chronic HCV patients with a current biopsy underwent a Medex Test (demographic characteristics- Table 1 ). The Medex Test was conducted in average 6.3 months after the biopsy (range 1 to 23 mo). The necroinflammatory grade in the biopsies was on average 2.05 with a median of 2. The Medex grading of necroinflammation matched the pathologic score in 47 cases (78%). In 7 cases there was a 1 point difference and in 6 cases a 2 point difference between the Medex Test grade and the pathologic biopsy-based grade. Rates underestimation was somewhat higher.
Statistical analysis demonstrated that agreement, presented by k, is significant with a k value of k = 0.704, P<0.001. To evaluate the effect of the covariates (sex, age, severity, and time between tests) on the accuracy of the test, due to the small number of degrees of freedom, the results of both tests, Medex Test and Biopsy grades, we recoded as 0, 1, 2 = low and 3, 4 = high. The k value slightly improved k = 0.772, P<0.001. When values of both biopsy grade and Medex Test results were recoded as (1, 2 = low and 3, 4 = high) the k value was k = 0.764, P<0.001.
For high values (3, 4) , corresponding with greater severity, the positive predictive value of the test was 100%. For low values (1, 2) positive predictive value is 84.6%. This difference was statistically significant (P<0.05). Additionally, we found that the accuracy of the Medex Test was not affected by sex or age (P = 0.515 and 1, respectively) nor was it affected by the time lag between the biopsy and the Medex Test (P = 1). Finally, as expected, Medex Test did not accurately detect the degree of fibrosis with a high rate of false positive results.
DISCUSSION
Current diagnosis of hepatic disease is a complex and often costly process. Liver enzymes tests are often negative in the presence of significant disease, 7, [22] [23] [24] or may be persistently elevated in the absence of an identifiable pathology. 25, 26 Serologic tests may not diagnose occult disease and may fail to distinguish between past and active disorders. 13, 27, 28 Moreover, even liver biopsy, an invasive costly technique which is considered the ''gold standard,'' is subject to sampling and interpretation errors [29] [30] [31] [32] and its use is controversial in many clinical scenarios. [33] [34] [35] [36] This has brought about a surge of novel diagnostic tests using new [37] [38] [39] and adapted [40] [41] [42] [43] [44] modalities in the understanding that no single test will replace its predecessors. Instead, new measures will be incorporated in existing diagnostic algorithms to enhance their costeffectiveness. In this study we have evaluated the efficacy of a novel test-Medex Test which is a development of a practiced branch of complementary medicine called neuroreflexology. This diagnostic test is intended to detect the presence of liver disorders and to assess their severity although it does not define the exact diagnosis. It has several advantages, namely, it is noninvasive, safe, relatively inexpensive, and is preformed in a short time.
Our first main finding is that the Medex Test detected, with high sensitivity and specificity, the presence of liver disease. High sensitivity was maintained for different liver diseases (HCV, HBV, and NAFLD) and regardless of patients' age and sex.
A second important finding is that the Medex Test has graded the degree of necroinflammation with 78% accuracy when compared with liver biopsy.
Although unable to provide data regarding to liver fibrosis, Medex Test detected the level of inflammation noninvasively in rates which are comparable with liver biopsy. Necroinflammatory grade may be valuable as a possible correlate with long-term outcome and in certain clinical considerations such as treatment initiation in advanced liver disease. [45] [46] [47] [48] Study limitations include the small sample size for hepatitis B and nonalcoholic fatty liver, which limits the statistical power of subgroup, by diagnosis analysis. Sample size was calculated to afford statistical power to the detection of disease as such (without giving the specific diagnosis), thus in future studies, an evaluation by specific diagnosis (eg, HCV, HBV etc.) should be conducted. Additionally, cases and controls were not well matched by sex. Finally, the control group underwent a comprehensive clinical evaluation yet only a limited laboratory evaluation. Thus, there may have been more undiagnosed liver disease in the control group which may bias the results. Nevertheless, we believe that stringent exclusion criteria applied, excluding all high risk groups, may have minimized this possible bias.
In conclusion, the evaluated diagnostic test has a high accuracy rate both for detecting the presence of liver disorders and for determining its severity. Further study is warranted to verify these results in larger cohorts and to determine the possible role of Medex Test in existing diagnostic algorithms. Additional studies may also further define the optimal thresholds for different clinical settings, allowing increased sensitivity when screening, or increased specificity for follow-up purposes.
